Latest Niemann–Pick disease Stories
- Vtesse to collaborate with National Institutes of Health on development of VTS-270 for Niemann-Pick Disease Type C and other novel drugs for life-threatening rare diseases GAITHERSBURG,
- Dr. Altstiel brings over 30 years of expertise in neurodegenerative diseases - NEWARK, N.J., Sept. 18, 2014 /PRNewswire/ -- Neurotrope, Inc.
Investment builds company strength in preparation for clinical trials. Alachua, Fla. (PRWEB) July 22, 2014 CTD Holdings, Inc.
- Neurotrope enters into world-wide, exclusive license agreement with Mount Sinai; Files related provisional patent for Bryostatin-1 - PLANTATION, Fla., July 22, 2014 /PRNewswire/
Dr. Jeffrey Tate promoted to CEO; C.E. Rick Strattan to serve as Executive Chairman. Alachua, FL (PRWEB) July 09, 2014 CTD Holdings, Inc.
Dr. Jeffrey Tate will chair 2016 event to be held in Gainesville, Fla. Alachua, Fla. (PRWEB) June 05, 2014 CTD Holdings, Inc.
Newly created Board positions will focus on corporate governance and capital markets programs. Alachua, FL (PRWEB) May 22, 2014 CTD Holdings, Inc., a
Investment establishes a strategic relationship with the USP Group for product development and marketing and adds new board member. Alachua, FL (PRWEB) April
Investment to speed development of orphan drug, other corporate goals. Alachua, FL (PRWEB) February 20, 2014 CTD Holdings, Inc.
As part of the multi-year agreement Gallus will provide process and method development, scale-up, clinical supply and preparation for commercial manufacturing for an infused protein-based therapy